PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models

Immune checkpoint inhibitors (CPIs) are associated with a number of immune-related adverse events and low response rates. We provide preclinical evidence for use of a retroviral replicating vector (RRV) selective to cancer cells, to deliver CPI agents that may circumvent such issues and increase eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, Leah A., Yagiz, Kader, Hofacre, Andrew, Viaud, Sophie, Munday, Anthony W., Espinoza, Fernando Lopez, Mendoza, Daniel, Rodriguez-Aguirre, Maria E., Bergqvist, Simon, Haghighi, Ali, Miner, Marin V., Accomando, William P., Burrascano, Cynthia, Gammon, Dawn, Gruber, Harry E., Jolly, Douglas J., Lin, Amy H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481342/
https://www.ncbi.nlm.nih.gov/pubmed/31040917
http://dx.doi.org/10.18632/oncotarget.26785

Ejemplares similares

Ejemplares similares